Rain Oncology Inc. (NASDAQ:RAIN – Get Free Report)’s stock price was up 2.7% during mid-day trading on Friday . The stock traded as high as $1.13 and last traded at $1.13. Approximately 75,462 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 642,508 shares. The stock had previously closed at $1.10.
Rain Oncology Price Performance
The business’s 50 day simple moving average is $0.96 and its 200 day simple moving average is $2.31. The stock has a market cap of $41.11 million, a P/E ratio of -0.44 and a beta of 0.22.
Rain Oncology (NASDAQ:RAIN – Get Free Report) last posted its earnings results on Thursday, August 10th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.12). Research analysts predict that Rain Oncology Inc. will post -1.67 earnings per share for the current year.
Insider Buying and Selling at Rain Oncology
Hedge Funds Weigh In On Rain Oncology
Large investors have recently modified their holdings of the stock. BML Capital Management LLC bought a new position in Rain Oncology in the 2nd quarter worth approximately $88,000. Ghost Tree Capital LLC acquired a new position in shares of Rain Oncology during the first quarter valued at $2,185,000. Sectoral Asset Management Inc. boosted its holdings in Rain Oncology by 2,479.4% in the first quarter. Sectoral Asset Management Inc. now owns 484,928 shares of the company’s stock valued at $4,238,000 after acquiring an additional 466,128 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in Rain Oncology in the first quarter worth about $495,000. Finally, GMT Capital Corp increased its position in Rain Oncology by 27.6% in the first quarter. GMT Capital Corp now owns 824,865 shares of the company’s stock worth $7,209,000 after purchasing an additional 178,607 shares during the period. 65.84% of the stock is currently owned by institutional investors and hedge funds.
About Rain Oncology
Rain Oncology Inc, a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53.
- Five stocks we like better than Rain Oncology
- How to Read Stock Charts for Beginners
- Shocking uranium play that hedge funds kept hidden
- What is Forex and How Does it Work?
- Dependable dividends: Why utility stocks are on fire
- How to Invest in Solar Energy
- Realtor verdict, poor revenue guidance send Zillow stock plunging
Receive News & Ratings for Rain Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rain Oncology and related companies with MarketBeat.com's FREE daily email newsletter.